reports
Pharming Group reports on results of the 2025 Annual General Meeting o...
Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders Leiden, the Netherlands, June 11, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that at its Annual General Meeting of Shareholders (AGM) held today, all proposals were approved. Dr. Elaine Sullivan, a seasoned leader in the international pharmaceutical and biotech industry with deep R&D expertise and public non-executive board experience, was appointed to the Pharming Board of Directors, upon binding recommendation of the Board of Directors, fo...
Pharming Group reports first quarter 2025 financial results and provid...
Pharming Group reports first quarter 2025 financial results and provides business update First quarter 2025 total revenues increased by 42% to US$79.1 million, compared to the first quarter 2024 RUCONEST® revenue increased by 49% to US$68.6 million, compared to the first quarter 2024, reflecting continued momentum and the product’s unique position in the on-demand HAE marketJoenja® (leniolisib) volume increase by 18% and revenue increased by 9% to US$10.5 million, compared to the first quarter of 2024, with accelerating patient uptake compared to the prior few quartersOperating profit, adju...
Pharming Group announces the 2025 Annual General Meeting of Shareholde...
Pharming Group announces the 2025 Annual General Meeting of Shareholders and the nomination of a new Non-Executive Director Leiden, the Netherlands, April 30, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces that the Company’s 2025 Annual General Meeting of Shareholders (the “AGM”) will be held on Wednesday June 11, 2025, at 14:00 CEST. The Notice to Convene, Explanatory Notes, Proxy and other meeting documents for the AGM can be found on the Company’s website under Investors/Shareholder Meetings. The Board of Directors has decide...
Pharming Group announces upcoming presentations at the 2025 Annual Mee...
Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) Leiden, the Netherlands, April 25, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces the following presentations by the Company or its collaborators at the 2025 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 1-4, 2025 in Philadelphia, PA. These presentations include Phase III clinical data for leniolisib for pediatric patients aged 4-11 years with activated phosphoinositide 3-kinase delta (PI3K...
Pharming receives positive recommendation from NICE for Joenja®▼(lenio...
Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the Netherlands, April 23, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces that the National Institute for Health and Care Excellence (NICE) has issued positive f...
Pharming Group announces the filing of its 2024 Annual Report and Form...
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “Period”). The Annual Report is available under Investors/Financial documents on the Pharming.com website. The Company also announces the filing of its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the Period. The 2024 Annual Report on Form 20-F can be found und...
Pharming Group announces first patient dosed in Phase II clinical tria...
Pharming Group announces first patient dosed in Phase II clinical trial of leniolisib for common variable immunodeficiency (CVID) with immune dysregulation Multi-center clinical trial includes sites located in the US, UK and EU Second Phase II clinical trial studying leniolisib for additional primary immunodeficiencies (PIDs) CVID patients demonstrate clinical phenotypes similar to APDS, with global prevalence estimated at approximately 39 per million Leiden, the Netherlands, March 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) an...
- Bruno Cavalier
- Roy Külter
- Steven Boumans
LI KLEPIERRE SA
COV COVIVIO SA
GFC GECINA SA
NXI NEXITY SA CLASS A
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
FLY SOCIETE FONCIERE LYONNAISE SA
GYC GRAND CITY PROPERTIES SA
STF STEF
MERY MERCIALYS SA
EL ESSILORLUXOTTICA SA
WHA WERELDHAVE N.V.
BLND BRITISH LAND COMPANY PLC
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
KOF KAUFMAN & BROAD SA
KER KERING SA
ALTA ALTAREA SCA
VNA VONOVIA SE
XIOR XIOR STUDENT HOUSING N.V.
ICAD ICADE SA
01913 PRADA S.P.A.
BYG BIG YELLOW GROUP PLC
COFB COFINIMMO SA
CAI CA IMMOBILIEN ANLAGEN AG
TEG TAG IMMOBILIEN AG
VASTB VASTNED RETAIL BELGIUM NV
LPP LPP S.A.
DLG DE'LONGHI S.P.A.
PSPN PSP SWISS PROPERTY AG
UBS UBM DEVELOPMENT AG
SPSN SWISS PRIME SITE AG
PAT PATRIZIA AG
MONT MONTEA SCA
AED AEDIFICA SA
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
CARM CARMILA SAS
LEG LEG IMMOBILIEN AG
MONC MONCLER SPA
CPINV CARE PROPERTY INVEST SA
SAFE SAFESTORE HOLDINGS PLC
ARG ARGAN SA
VGP VGP NV
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
COL INMOBILIARIA COLONIAL SOCIMI SA
DIC DIC ASSET AG
MERLIN MERLIN PROPERTIES SOCIMI S.A.
DKG DEUTSCHE KONSUM REIT-AG
HOME NEINOR HOMES SA
AT1 AROUNDTOWN SA
IMP IMPACT DEVELOPER & CONTRACTOR S.A.
LAND LAND SECURITIES GROUP PLC
MVC METROVACESA SA
NSI NSI N.V.
ULA UNIBAIL-RODAMCO-WESTFIELD SE STAPLED SECS CONS OF 1 SH UNIBAIL RODAMCO + 1 SH WFD UNIB ROD
INS INSTONE REAL ESTATE GROUP AG
AEDAS AEDAS HOMES SA
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
WDP WAREHOUSES DE PAUW SCA
ECMPA EUROCOMMERCIAL PROPERTIES NV
ALLFG ALLFUNDS (UK) LTD
CTPNV CTP NV
ONE ONE UNITED PROPERTIES SA
SHUR SHURGARD SELF STORAGE LIMITED
- Jeremy Garnier
- Bruno Cavalier
- Christophe Chaput
- Hela Zarrouk
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
GYC GRAND CITY PROPERTIES SA
STF STEF
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
VIRP VIRBAC SA
KER KERING SA
01913 PRADA S.P.A.
LPP LPP S.A.
DLG DE'LONGHI S.P.A.
UBS UBM DEVELOPMENT AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
MONC MONCLER SPA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
NSI NSI N.V.
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
ALLFG ALLFUNDS (UK) LTD
- Jeremy Garnier
Résultats annuels 2024 d’Hoffmann Green : solides performances commerc...
CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)-- Regulatory News: Hoffmann Green Cement Technologies (ISIN : FR0013451044, Mnémo : ALHGR) (« Hoffmann Green Cement »), acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, fait le point sur ses activités et annonce ses résultats annuels 2024. Le Conseil de Surveillance de la société s’est réuni le 14 mars 2025 et a examiné les comptes de l’exercice 2024 arrêtés par le Directoire. Les procédures d’audit ont été effectuées et le rapport d’audit relatif à la...
Pharming Group reports fourth quarter and full year 2024 financial res...
Pharming Group reports fourth quarter and full year 2024 financial results and provides business update Full year 2024 total revenues increased by 21% to US$297.2 million and exceeded our guidance, driven by record RUCONEST® revenue and strong Joenja® (leniolisib) growth Fourth quarter 2024 total revenues increased by 14% to US$92.7 million, compared to the fourth quarter 2023RUCONEST® full year revenue increased by 11% to US$252.2 million and fourth quarter revenue increased by 9% to US$79.6 million, compared to the fourth quarter 2023Joenja® revenue increased by 147% to US$45.0 million in...
Première mondiale : le ciment décarboné H-UKR 0% clinker d'Hoffmann Gr...
CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)-- Hoffmann Green Cement Technologies (ISIN : FR0013451044, mnémo : ALHGR) (« Hoffmann Green Cement » ou la « Société »), un acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, annonce aujourd'hui avoir obtenu un Avis Technique (ATEc) pour son ciment H-UKR, une première mondiale pour un ciment 0% clinker, confirmant une fois de plus le leadership technologique de la Société dans le secteur de la construction. Fruit de plus de sept années de recherche, d'ess...
Première mondiale : le ciment décarboné H-UKR 0% clinker de Hoffmann G...
CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)-- Regulatory News: Hoffmann Green Cement Technologies (ISIN : FR0013451044, Mnémo : ALHGR) (« Hoffmann Green Cement »), acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, annonce l’obtention d’un Avis Technique (ATEc) pour son ciment décarboné H-UKR, une première mondiale pour un ciment 0% clinker, confirmant une nouvelle fois le leadership technologique de la Société parmi les acteurs du secteur de la construction. Fruit de plus de sept années de recher...
World Premiere: H-UKR Decarbonized Cement 0% Clinker From Hoffmann Gre...
CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)-- Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative clinker-free cements, today announced that it has obtained a Technical Approval (ATEc) for its H-UKR cement, a world premiere for a 0% clinker cement, confirming once again the Company's technological leadership in the construction sector. Resulting from more than seven years of research, rigorous testing, collaborat...
Hoffmann Green accélère son partenariat avec Trecobat, 3ème constructe...
CHAILLÉ-SOUS-LES-ORMEAUX, France--(BUSINESS WIRE)-- Regulatory News: Hoffmann Green Cement Technologies (ISIN : FR0013451044, Mnémo : ALHGR) (« Hoffmann Green Cement »), acteur industriel engagé dans la décarbonation du secteur de la construction qui conçoit et commercialise des ciments innovants sans clinker, annonce l’extension de son partenariat avec le Groupe Trecobat, 3e constructeur de maisons individuelles en France. Dès mars 2025, les ciments décarbonés 0% clinker Hoffmann Green seront déployés sur plus de 100 chantiers de maisons Trecobat dans le Grand Ouest de la France. Créé en 19...
Pharming Group reports on results of the 2025 Extraordinary General Me...
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda. Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth hand-over of...
Pharming Group to participate in March investor conference
Pharming Group to participate in March investor conference Leiden, the Netherlands, February 28, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conference in the month of March: 37th Annual Roth Conference, Dana Point, CA, USA, March 16-18, 2025Anurag Relan, Chief Medical Officer, and Michael Levitan, VP Investor Relations and Corporate Communications, will participate in a fireside chat question and answer session on Monday, March 17 at 01:30pm PT/21:30 CET. For more informati...
Pharming Group to report fourth quarter and full year 2024 financial r...
Pharming Group to report fourth quarter and full year 2024 financial results on March 13 Leiden, the Netherlands, February 27, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2024 financial results, for the period ended December 31, on Thursday, March 13, 2025. Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 13, 2025. To participate in the conference call, please register in advance using the link below. Once registered, dial-in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.